Citations

Showing 10 of 108083 citations.

More Than Likes and Tweets: Creating Social Media Portfolios for Academic Promotion and Tenure
Cabrera, Daniel , Vartabedian, Bryan S., Spinner, Robert J. , Jordan, Barbara L., Aase, Lee , Timimi, Farris K. , Cabrera, Daniel

Mayo Clinic

Journal of Graduate Medical Education | August 15, 2017 | Volume: 9 | Issue: 4 | Pages: 421-425

10.4300/jgme-d-17-00171.1 | PMID 28824752 Get It

Shared Decision Making and Improving Health Care
Kunneman, Marleen , Brito, Juan P. , Montori, Víctor M. , Brito, Juan P

Mayo Clinic

JAMA | August 15, 2017 | Volume: 318 | Issue: 7 | Pages: 617

10.1001/jama.2017.10168 | PMID 28810005 Get It

A Tupaia paramyxovirus vector system for targeting and transgene expression
Engeland, Christine E. , Bossow, Sascha, Hudacek, Andrew W., Hoyler, Birgit, Förster, Judith M., Veinalde, Rūta , Jäger, Dirk, Cattaneo, Roberto , Ungerechts, Guy , Springfeld, Christoph

Mayo Clinic

Journal of General Virology | August 15, 2017 | Volume: 98 | Issue: 9 | Pages: 2248-2257

10.1099/jgv.0.000887 | PMID 28809150 Get It

IRF4 Modulates CD8+ T Cell Sensitivity to IL-2 Family Cytokines
Huang, Su, Shen, Yingjia, Pham, Duy , Jiang, Li , Wang, Zheng , Kaplan, Mark H. , Zhang, Guangjun , Kaplan, Mark H , Sun, Jie

Mayo Clinic

ImmunoHorizons | August 15, 2017 | Volume: 1 | Issue: 6 | Pages: 92-100

10.4049/immunohorizons.1700020 | PMID 29564420 Get It

Abstract IFN regulatory factor 4 (IRF4) is a key transcription factor that promotes effector CD8+ T cell differentiation and expansion. The roles of IRF4 in regulating the CD8+ T cell response to cytokines have not been explored. In this article, we show that IL-2 and IL-15 signaling and STAT5 activation regulate IRF4 expression in CD8+ T cells. Gene-expression profile analysis has also revealed that IRF4 is required for expression of the receptors of IL-2 family cytokines CD122 and CD127. We found that IRF4 binds directly to CD122 and CD127 gene loci, indicating that it may directly promote CD122 and CD127 gene transcription. As a consequence, IRF4-deficient CD8+ T cells show diminished sensitivity to IL-2, IL-15, and IL-7 treatment in vitro. Furthermore, we found that IRF4-deficient CD8+ T cells had lower expression of CD122 and CD127 in vivo during influenza virus infection. These data suggest that IRF4 regulates the sensitivity of CD8+ T cells to IL-2 family cytokines, which correlates with the diminished effector and memory CD8+ T cell responses in IRF4-deficient CD8+ T cells.
Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
Hwa, Yi L. , Warsame, Rahma , Gertz, Morie A. , Buadi, Francis K. , Lacy, Martha Q. , Kumar, Shaji , Dingli, David , Zeldenrust, Steve R., Hayman, Susanne R., Kapoor, Prashant , Kourelis, Taxiarchis , Russell, Stephen J. , Hobbs, Miriam, Fonder, Amie , Dispenzieri, Angela , Gertz, Morie A , Buadi, Francis K , Russell, Stephen J , Dingli, David , Zeldenrust, Steven R., Leung, Nelson , Gonsalves, Wilson I. , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | August 14, 2017 | Volume: 130 | Issue: 13 | Pages: 1578-1584

10.1182/blood-2017-05-783415 | PMID 28807981 Get It

Key Points Organ progression at second-line therapy predicated inferior survival. Patients relapsing from >VGPR had a longer time to develop organ progression.
S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma
Chow, Kin-Hoe, Park, Hee Jung , Yamamoto, Keiko , Gallup, Andrew D., Chen, Yuanxin , Jiang, Wen , Steindler, Dennis A. , Neilson, Eric G. , Kim, Betty Y.S. , Yun, Kyuson , Jiang, Wen , Kim, Betty Y S , George, Joshy , Graber, Joel H.

Mayo Clinic

Cancer Research | August 14, 2017 | Volume: 77 | Issue: 19 | Pages: 5360-5373

10.1158/0008-5472.can-17-1294 | PMID 28807938 Get It

Abstract Glioma stem cells (GSC) and epithelial–mesenchymal transition (EMT) are strongly associated with therapy resistance and tumor recurrence, but the underlying mechanisms are incompletely understood. Here, we show that S100A4 is a novel biomarker of GSCs. S100A4+ cells in gliomas are enriched with cancer cells that have tumor-initiating and sphere-forming abilities, with the majority located in perivascular niches where GSCs are found. Selective ablation of S100A4-expressing cells was sufficient to block tumor growth in vitro and in vivo. We also identified S100A4 as a critical regulator of GSC self-renewal in mouse and patient-derived glioma tumorspheres. In contrast with previous reports of S100A4 as a reporter of EMT, we discovered that S100A4 is an upstream regulator of the master EMT regulators SNAIL2 and ZEB along with other mesenchymal transition regulators in glioblastoma. Overall, our results establish S100A4 as a central node in a molecular network that controls stemness and EMT in glioblastoma, suggesting S100A4 as a candidate therapeutic target. Cancer Res; 77(19); 5360–73. ©2017 AACR.
Effect of integrated community neurology on utilization, diagnostic testing, and access
Elrashidi, Muhamad Y. , Philpot, Lindsey M. , Ramar, Priya , Swanson, Kristi M. , Crane, Sarah J. , Ebbert, Jon O. , Young, Nathan P. , McKie, Paul M. , Philpot, Lindsey M

Mayo Clinic

Neurology Clinical Practice | August 14, 2017 | Volume: 7 | Issue: 4 | Pages: 306-315

10.1212/cpj.0000000000000378 | PMID 28840913 Get It

Response to Letter by Dr. Champion
Dawson, Nancy L. , Dawson, Nancy

Mayo Clinic

Pain Medicine | August 14, 2017 | Volume: 19 | Issue: 2 | Pages: 414-414

10.1093/pm/pnx226 | PMID 29161450 Get It

Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes
Rottenstreich, Amihai , Kleinstern, Geffen , Spectre, Galia, Da’as, Nael, Ziv, Esther, Kalish, Yosef

Mayo Clinic

World Journal of Surgery | August 14, 2017 | Volume: 42 | Issue: 3 | Pages: 675-681

10.1007/s00268-017-4185-2 | PMID 28808782 Get It

AbstractBackgroundThromboembolic events following splenectomy are not uncommon. However, the role of thromboprophylaxis and risk factors for thrombosis, as well as the clinical course and outcomes, are not well characterized.MethodsA retrospective review of individuals who underwent splenectomy between January 2006 and December 2015 in two university hospitals.ResultsOverall, 297 patients underwent splenectomy [open splenectomy (n = 199), laparoscopic splenectomy (n = 98)]. Mechanical (thigh‐length pneumatic compression stockings) and pharmacologic thromboprophylaxis (40 mg enoxaparin daily, starting 12 h after surgery until discharge) was provided for all patients. One hundred and sixteen patients (39%) also received an extended thromboprophylaxis course of enoxaparin for 2–4 weeks after discharge. Twenty‐three patients (7.7%) experienced thrombotic complications following splenectomy, including 16 cases (5.4%) of portal‐splenic mesenteric venous thrombosis (PSMVT), 5 (1.7%) pulmonary embolism and 2 (0.7%) deep vein thrombosis. Longer operative time (mean operative time of 405 vs. 273 min, P = 0.03) was independently associated with PSMVT. Post‐splenectomy thrombocytosis was not associated with thrombosis (P = 0.41). The overall thrombosis rate was significantly lower in patients who received an extended thromboprophylaxis course following splenectomy (3.4 vs. 10.5%, P = 0.02). Complete resolution of thrombosis was observed in most cases (n = 20, 87.0%), with no recurrent thrombosis during a mean follow‐up of 38 ± 25 months.ConclusionsThromboembolic complications, mainly PSMVT, are common following splenectomy. Longer operative time was associated with thrombosis. Significantly lower rates of thrombosis were found in patients who received an extended thromboprophylaxis course.
Eliminating Creatine Kinase–Myocardial Band Testing in Suspected Acute Coronary Syndrome
Jaffe, Allan S. , Ziegelstein, Roy C. , Trost, Jeffrey C. , Alvin, Matthew D. , Jaffe, Allan S.

Mayo Clinic

JAMA Internal Medicine | August 14, 2017 | Volume: 177 | Issue: 10 | Pages: 1508

10.1001/jamainternmed.2017.3597 | PMID 28806444 Get It